tiprankstipranks
Kaken Pharmaceutical Co Ltd (KKPCF)
OTHER OTC:KKPCF
Want to see KKPCF full AI Analyst Report?

Kaken Pharmaceutical Co (KKPCF) Price & Analysis

4 Followers

KKPCF Stock Chart & Stats

$23.65
-$2.42(-8.28%)
At close: 4:00 PM EST
$23.65
-$2.42(-8.28%)

Bulls Say, Bears Say

Bulls Say
Conservative Balance SheetKaken's very low leverage and large equity base provide durable financial flexibility. A conservative balance sheet cushions the company during revenue or cash-flow shocks, supports continued R&D funding or opportunistic M&A, and reduces default risk versus peers over the medium term.
Specialist Dermatology FocusA focused specialty franchise in dermatology supports durable demand and deeper clinical relationships with prescribers. Selling branded drugs through Japan's NHI and established distribution channels creates predictable reimbursement dynamics and structural market access for core products.
Prior Strong Cash Generation & DividendHistorically strong FCF and a meaningful dividend signal the business can generate shareholder cash in normal operating years. This track record supports continued investment in pipeline and the credibility of shareholder distributions if cash generation normalizes.
Bears Say
Sharp Revenue And Margin DeclineA near-20% revenue drop and collapse in operating margins materially weaken the firm's earnings foundation. Sustained top-line pressure reduces internal funding for R&D and commercialization, forcing restructuring or repricing decisions that can impair medium-term growth and competitive positioning.
Material Negative Cash FlowTurnaround to negative operating and free cash flow raises execution and liquidity risk. If cash generation does not recover, management may need to cut R&D, halt launches, reduce dividends, or use balance-sheet resources, which would constrain long-term pipeline investment and growth.
Earnings Volatility And Weakening ReturnsA sharp drop in ROE and steep EPS decline indicate volatile earnings quality. Persistent earnings instability undermines reinvestment capacity and investor confidence, complicates long-term planning, and raises the bar for management to demonstrate sustained recovery in profitability.

KKPCF FAQ

What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was $20.68 and its highest was $30.84 in the past 12 months.
    What is Kaken Pharmaceutical Co Ltd’s market cap?
    Kaken Pharmaceutical Co Ltd’s market cap is $941.86M.
      When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 12, 2026 which is in 88 days.
        How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
        Kaken Pharmaceutical Co Ltd released its earnings results on May 13, 2026. The company reported $0.124 earnings per share for the quarter, missing the consensus estimate of $0.126 by -$0.002.
          Is Kaken Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kaken Pharmaceutical Co Ltd pay dividends?
            Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of $0.605 which represents an annual dividend yield of 4.34%. See more information on Kaken Pharmaceutical Co Ltd dividends here
              What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
              Kaken Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
              Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
                What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
                Kaken Pharmaceutical Co Ltd reported an EPS of $0.124 in its last earnings report, missing expectations of $0.126. Following the earnings report the stock price went down -1.054%.
                  Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
                  Currently, no hedge funds are holding shares in KKPCF
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Kaken Pharmaceutical Co Ltd

                    Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

                    Kaken Pharmaceutical Co (KKPCF) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Kissei Pharmaceutical Co
                    Towa Pharmaceutical Co
                    Mochida Pharmaceutical Co., Ltd.
                    KYORIN Pharmaceutical Co.,Ltd.
                    SAWAI GROUP HOLDINGS Co., Ltd.

                    Ownership Overview

                    3.77%93.33%
                    Insiders
                    ― Other Institutional Investors
                    93.33% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks